|
**Overview**: HOMA-IR C-Peptide Panel**Introduction**: The HOMA-IR C-Peptide Panel is a diagnostic tool designed to assess insulin resistance with C-peptide using serum samples. In India, C-peptide-based HOMA-IR provides better accuracy in insulin-resistant states or when exogenous insulin is used, common in type 2 diabetes and PCOS. High morbidity from under-testing in rural/low-SES patients with metabolic syndrome, limited labs, delayed intervention leading to diabetes progression or CVD. Per endocrinology practices aligned with ICMR and RSSDI guidelines, the test employs spectrophotometry for fasting glucose, C-peptide, HOMA-IR index, HOMA-Beta, and insulin sensitivity over 1-2 days with high accuracy, valuable for insulin dynamics evaluation. This diagnostic falls under metabolic screening and targets patients with suspected insulin resistance or on insulin therapy, addressing accurate detection to guide therapy optimization. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise metabolic profiling and reducing complications. Its serum-based approach ensures reliable calculation.**Other Names**: HOMA-IR C-Pep Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: C-peptide HOMA-IR standard; in India, used in diabetes clinics.**Purpose**: The test assesses 5 parameters including fasting glucose to guide insulin resistance evaluation with C-peptide, calculate indices, inform therapy.**Test Parameters**: 1. Fasting Glucose, 2. C-Peptide, 3. HOMA-IR Index, 4. HOMA-Beta, 5. Insulin Sensitivity.**Pretest Condition**: Fasting 10-12 hours required; patients should report metabolic risk factors.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on weight, diabetes treatment, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected resistance including progression, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and calculate indices within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or non-fasting can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High HOMA-IR/low HOMA-Beta indicates resistance/beta-cell dysfunction, necessitating specialist input.**Specialist Consultation**: Diabetologists should be consulted for management.**Additional Supporting Tests**: OGTT, HbA1c for confirmation.**Test Limitations**: Fasting-dependent; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Metabolic Studies India 2023. |
